Monday, June 25, 2007 - 18:31

Innate Pharma S.A. announced that IPH 2101 (NN 1975), developed by Novo Nordisk A/S in collaboration with the Company, was administered for the first time in patients suffering from multiple myeloma.

AttachmentSize
PR in english57.57 KB
CP en français42.36 KB